Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

by | Jun 22, 2026 | Clinical Trials | 0 comments

​ Conditions: Solid Tumors

Interventions: Drug: Asprin; Drug: Loratadine; Behavioral: Acetaminophen Avoidance; Behavioral: THC Avoidance

Sponsors: Val Adams

Not yet recruiting Conditions: Solid Tumors
Interventions: Drug: Asprin; Drug: Loratadine; Behavioral: Acetaminophen Avoidance; Behavioral: THC Avoidance
Sponsors: Val Adams
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *